Investigating shared mechanisms of tau toxicity in neurodegenerative diseases
Official title: Shared Mechanisms of Tau Toxicity Among Neurodegenerative Diseases
Funded at Stanford University · NIH-11130576 · Data updated 2026-11-12
This study is looking at how problems with a protein called tau might be linked to diseases like Alzheimer's and Frontotemporal Dementia, with the hope of finding new ways to treat these conditions that could help patients in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | June 1, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $763,922 |
| NIH project number | 1R01AG089752-01A1 |
| Project ID | NIH-11130576 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, Frontotemporal Dementia, or other tau-related neurodegenerative disorders.
✕Less likely to help
Patients with neurodegenerative diseases not associated with tau pathology, such as certain forms of motor neuron disease, may not benefit from this research.
What this research studies
This research explores the common pathological features of neurodegenerative diseases, particularly focusing on the role of tau protein abnormalities. By examining how tau hyperphosphorylation and aggregation contribute to conditions like Alzheimer's disease and Frontotemporal Dementia, the study aims to identify shared mechanisms that could be targeted therapeutically. The research utilizes advanced techniques, including CRISPR technology, to manipulate tau levels and assess their impact on mitochondrial function and disease progression. Patients may benefit from insights that could lead to new treatment strategies for a range of neurodegenerative disorders.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that alleviate symptoms or slow the progression of multiple neurodegenerative diseases.
How similar studies have gone: Previous research has shown promising results in targeting tau abnormalities in animal models, suggesting potential for success in human applications.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Lu, Bingwei — Stanford University
- Study coordinator: Lu, Bingwei
Related research
Other NIH-funded projects on the same topics.
-
Developing small molecules to treat TDP-43 related brain diseases
A potential new drug candidate (XL20) for diseases like Alzheimer’s and other dementias linked to TDP-43 protein problems is being developed and refined for people who live with these conditions.
-
Tau filament structure in Alzheimer’s and related dementias
Aims to map the detailed 3D shapes of tau protein filaments found in human brain diseases to help develop better diagnostics and treatments for Alzheimer’s-related dementias.
-
Targeting RNA Splicing Abnormalities in ALS/FTD
A research team aims to understand and correct abnormal RNA splicing in ALS and related brain diseases to help patients in the future.
-
Blood-brain barrier–friendly imaging agents for neurodegenerative diseases
A researcher team will test new imaging agents that can cross the brain barrier to help detect Alzheimer’s and related diseases earlier and more accurately.
-
Brain cell–derived EV markers to differentiate Alzheimer’s and related dementias
A Mayo Clinic team is testing brain-cell–specific tiny particles in blood to tell apart Alzheimer’s disease and similar dementias using advanced machine-learning analysis.
-
Fisetin approach to reduce vulnerability to community infections in aging veterans
A patient-friendly look at a study testing whether the natural compound fisetin can help aging Veterans stay healthier when they face common infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.